Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

81. Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease Full Text available with Trip Pro

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease Loss of renal function is associated with high mortality from cardiovascular disease (CVD). Patients with chronic kidney disease (CKD) have altered circulating adipokine and nonesterified fatty acid concentrations and insulin resistance, which are features of disturbed adipose tissue metabolism. Because dysfunctional adipose tissue contributes to the development of CVD, we hypothesize that adipose tissue

2017 Kidney international reports

82. Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine Full Text available with Trip Pro

Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine Chronic kidney disease (CKD) is a major public health concern in the United States with high prevalence, growing incidence, and serious adverse outcomes.We aimed to develop and validate a model to identify patients at risk of receiving a new diagnosis of CKD (incident CKD) during the next 1 year in a general population.The study

2017 JMIR medical informatics

83. Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease Full Text available with Trip Pro

Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease 29270536 2019 02 26 2468-0249 2 6 2017 Nov Kidney international reports Kidney Int Rep Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease. 1254-1258 10.1016/j.ekir.2017.07.003 Gaudreault-Tremblay Marie-Michèle MM Division of Nephrology, The Hospital for Sick (...) of Toronto, Toronto, Ontario, Canada. Lemaire Mathieu M Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. eng Case Reports 2017 07 20 United States Kidney Int Rep 101684752 2468-0249 2017 12 23 6 0 2017 12 23 6 0 2017 12 23 6 1 epublish 29270536 10.1016/j.ekir.2017.07.003 S2468-0249(17)30301-7 PMC5733878 J Am Soc Nephrol. 2012 Jul;23(7):1140-8 22626822 Pediatr Nephrol. 2010 Jul;25(7):1225-38

2017 Kidney international reports

84. Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease Full Text available with Trip Pro

Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease Chronic kidney disease (CKD) patients have increased risks of sudden cardiac arrest and sudden cardiac death (SCA/SCD) that are not explained by traditional risk factors. We examined associations between serum potassium and SCA/SCD in a large cohort of patients with coronary artery disease (CAD) and moderate CKD.Among 22,009 patients who underwent cardiac (...) catheterization at our institution between 1999 and 2011, 6181 patients had an estimated glomerular filtration rate of ≤60 ml/min per 1.73 m2 and were not receiving renal replacement therapy. The risk of SCA/SCD and all-cause mortality associated with potassium concentration was evaluated at the time of cardiac catheterization (baseline) and most proximate to SCA/SCD events. Covariate-adjusted Cox models were used to examine relationships between baseline potassium measurements and outcomes. A propensity

2017 Kidney international reports

85. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure Full Text available with Trip Pro

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure This study investigated the relationship between the initial diuretic response to tolvaptan and clinical predictors for tolvaptan responders in patients with acute decompensated heart failure (ADHF).Patients (153) with ADHF (clinical scenario 2 or 3 with signs of fluid retention) who were administered tolvaptan were enrolled. Tolvaptan (15 or 7.5 mg) was administered for at least 7 days (...) to those patients in whom fluid retention was observed even after standard treatment. The maximum urine volume immediately after tolvaptan administration showed good correlations with the ejection fraction and estimated glomerular filtration rate that were independent predictors of the urine volume (UV) responders (≥1500 mL increase in urine volume). The diuretic response (in terms of maximum diuresis) diminished with advancing chronic kidney disease (CKD) stage and concomitant deterioration

2017 ESC heart failure

86. Chronic kidney disease and the global NCDs agenda Full Text available with Trip Pro

Chronic kidney disease and the global NCDs agenda 29225940 2019 01 31 2059-7908 2 2 2017 BMJ global health BMJ Glob Health Chronic kidney disease and the global NCDs agenda. e000380 10.1136/bmjgh-2017-000380 Neuen Brendon Lange BL Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia. Renal and Metabolic Division, George Institute for Global Health, Sydney, Australia. Chadban Steven James SJ Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia (...) . Charles Perkins Centre, University of Sydney, Sydney, Australia. Demaio Alessandro Rhyl AR World Health Organization, Geneva, Switzerland. Johnson David Wayne DW Centre for Kidney Disease Research, University of Queensland, Brisbane, Australia. Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia. Translational Research Institute, Brisbane, Australia. Perkovic Vlado V Renal and Metabolic Division, George Institute for Global Health, Sydney, Australia. Department of Renal Medicine

2017 BMJ global health

87. Interventions for chronic kidney disease in people with sickle cell disease. Full Text available with Trip Pro

Interventions for chronic kidney disease in people with sickle cell disease. Sickle cell disease (SCD) is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta-globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD.Chronic kidney disease is defined as abnormalities of kidney structure (...) searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register: 13 April 2017.Randomised controlled trials comparing interventions to prevent or reduce kidney complications or chronic kidney disease in people with SCD. There were no restrictions by outcomes examined, language or publication status.Two authors independently assessed trial eligibility, extracted data and assessed the risk of bias.We included two trials with 215 participants. One trial was published in 2011 and included

2017 Cochrane

88. [Intradialytic parenteral nutrition in patients with chronic kidney conditions]

[Intradialytic parenteral nutrition in patients with chronic kidney conditions] [Intradialytic parenteral nutrition in patients with chronic kidney conditions] [Intradialytic parenteral nutrition in patients with chronic kidney conditions] Molinari LM, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Molinari LM, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A. [Intradialytic parenteral nutrition in patients with chronic kidney conditions] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 528. 2017 Authors' conclusions Scarce evidence of moderate quality shows that in hemodialyzed patients, Intradialytic

2017 Health Technology Assessment (HTA) Database.

89. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis

to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 432 2 Clinical need and pr Clinical need and practice actice The problem addressed 2.1 The purpose of this assessment is to evaluate the clinical and cost effectiveness of using multiple frequency bioimpedance devices to monitor the hydration status of a person with chronic kidney disease who is having either haemodialysis or peritoneal dialysis treatment. 2.2 Dialysis is used to replace renal function (...) ), kidney failure occurs and renal replacement therapy (transplantation or dialysis) is needed for survival. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 432.5 Dialysis replicates many of the functions of a healthy kidney, for example, filtering waste products and excess water from

2017 National Institute for Health and Clinical Excellence - Diagnostics Guidance

90. Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker Full Text available with Trip Pro

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to <60 ml/min per 1.73 m2.In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR ≥ 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE (...)  improved the net reclassification index (P ≤ 0.0003), except for UAE per threshold (P = 0.086).In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.

2017 Kidney international reports

91. Chronic Kidney Disease in Panama: Results From the PREFREC Study and National Mortality Trends Full Text available with Trip Pro

Chronic Kidney Disease in Panama: Results From the PREFREC Study and National Mortality Trends The magnitude of chronic kidney disease (CKD) in Panama has yet to be described. We investigated the association between sociodemographic and cardiovascular exposures with CKD in 2 Panamanian provinces. Further, we analyzed national trends of CKD mortality from 2001 to 2014.Data were derived from Prevalencia de Factores de Riesgo de Enfermedad Cardiovascular (PREFREC [Survey on Risk Factors Associated (...) With Cardiovascular Disease]), a cross-sectional study designed to analyze the prevalence of risk factors associated with cardiovascular disease. Biomarkers of kidney function were measured in 3590 participants. CKD was defined as an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m2 and/or albuminuria ≥30 mg/g creatinine. Odds ratios (ORs) with 95% confidence intervals (CIs) for CKD were calculated using logistic regression. We calculated age-standardized CKD mortality rates in the country using

2017 Kidney international reports

92. Chronic kidney disease in low-income to middle-income countries: the case for increased screening Full Text available with Trip Pro

Chronic kidney disease in low-income to middle-income countries: the case for increased screening Chronic kidney disease (CKD) is fast becoming a major public health issue, disproportionately burdening low-income to middle-income countries, where detection rates remain low. We critically assessed the extant literature on CKD screening in low-income to middle-income countries. We performed a PubMed search, up to September 2016, for studies on CKD screening in low-income to middle-income (...) countries. Relevant studies were summarised through key questions derived from the Wilson and Jungner criteria. We found that low-income to middle-income countries are ill-equipped to deal with the devastating consequences of CKD, particularly the late stages of the disease. There are acceptable and relatively simple tools that can aid CKD screening in these countries. Screening should primarily include high-risk individuals (those with hypertension, type 2 diabetes, HIV infection or aged >60 years

2017 BMJ global health

93. Re: Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases Full Text available with Trip Pro

Re: Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases 29142994 2019 01 18 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Re: Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases. 779 10.1016/j.ekir.2017.05.005 Auguste Bourne L BL Division of Nephrology, University of Toronto, Toronto Ontario, Canada, on behalf of the University of Toronto (...) City-wide Nephrology Journal Club. Naimark David M J DMJ Division of Nephrology, University of Toronto, Toronto Ontario, Canada, on behalf of the University of Toronto City-wide Nephrology Journal Club. eng Journal Article 2017 05 12 United States Kidney Int Rep 101684752 2468-0249 2017 04 26 2017 05 05 2017 11 17 6 0 2017 11 17 6 0 2017 11 17 6 1 epublish 29142994 10.1016/j.ekir.2017.05.005 S2468-0249(17)30120-1 PMC5678618 J Am Soc Nephrol. 2003 Nov;14(11):2934-41 14569104 J Am Soc Nephrol. 2009

2017 Kidney international reports

94. The Association of Daily Activity Levels and Estimated Kidney Function in Men and Women With Predialysis Chronic Kidney Disease Full Text available with Trip Pro

The Association of Daily Activity Levels and Estimated Kidney Function in Men and Women With Predialysis Chronic Kidney Disease Chronic kidney disease (CKD) is often accompanied by complications including poor physical activity level. However, only a few studies have objectively characterized physical activity levels in predialysis CKD. Our study sought to measure daily activity levels by accelerometry in individuals with CKD (stages III-V) and to determine the association between daily (...) activity and kidney function.We determined kidney function by means of the estimated glomerular filtration rate (eGFR) using the Modification of Diet and Renal Disease (MDRD) equation. Participants wore an accelerometer for 7 consecutive days, and we measured multiple physical activity outcomes including total daily activity, sedentary, light, and moderate-vigorous activity. Average durations and intensity of activity were determined according to stage of CKD. The association between kidney function

2017 Kidney international reports

95. Association of Sleep Duration, Symptoms, and Disorders With Mortality in Adults With Chronic Kidney Disease Full Text available with Trip Pro

Association of Sleep Duration, Symptoms, and Disorders With Mortality in Adults With Chronic Kidney Disease In general populations, short and long sleep duration, poor sleep quality and sleep disorders have been associated with increased risk of death. We evaluated these associations in individuals with chronic kidney disease (CKD).Prospective cohort study of 1,452 National Health and Nutrition Examination Survey (NHANES) 2005-2008 participants with CKD. CKD was defined by estimated glomerular (...) filtration rate <60 ml/min/1.73m2 or urine albumin-to-creatinine ratio ≥30 mg/g. Sleep duration, sleep symptoms (difficulty falling asleep, difficulty staying asleep, daytime sleepiness and non-restorative sleep), and sleep disorders (restless legs syndrome and sleep apnea) were self-reported. Vital status was determined using NHANES mortality linkage through December 2011.Mean age was 61 years, 58% were women, and 75% non-Hispanic white. During 4.4 years of median follow-up, we observed 234 deaths

2017 Kidney international reports

96. Examining the Roles and Experiences of Fathers of Children With Chronic Kidney Disease Full Text available with Trip Pro

Examining the Roles and Experiences of Fathers of Children With Chronic Kidney Disease This study examined roles and experiences of fathers of children with chronic kidney disease (CKD). Based on interpretive description, semistructured interviews were conducted with 22 fathers of children receiving a range of treatments (transplant, peritoneal dialysis, hemodialysis, and CKD not requiring renal replacement therapy). Fathers described various experiences and means of adjusting to shifts

2017 Global qualitative nursing research

97. Dietary interventions for adults with chronic kidney disease. Full Text available with Trip Pro

Dietary interventions for adults with chronic kidney disease. Dietary changes are routinely recommended in people with chronic kidney disease (CKD) on the basis of randomised evidence in the general population and non-randomised studies in CKD that suggest certain healthy eating patterns may prevent cardiovascular events and lower mortality. People who have kidney disease have prioritised dietary modifications as an important treatment uncertainty.This review evaluated the benefits and harms (...) of dietary interventions among adults with CKD including people with end-stage kidney disease (ESKD) treated with dialysis or kidney transplantation.We searched the Cochrane Kidney and Transplant Specialised Register (up to 31 January 2017) through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference

2017 Cochrane

98. Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease Full Text available with Trip Pro

Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease The production of erythrocytes is regulated by the hormone erythropoietin (EPO), which maintains the blood haemoglobin (Hb) levels constant under normal conditions. Human EPO is a glycoprotein hormone and its synthesis is controlled by the hypoxia-inducible transcription factor. The aim of this study was to establish EPO and Hb levels in patients with chronic kidney disease (CKD (...) CKD patients had significantly lower levels of haemoglobin (p<0.0005) and hematocrit (p<0.0005) compared to control group. Our results showed that Hb levels decreased, whereas serum creatinine increased with the increasing renal failure. The CKD patients in all four groups had significantly lower (p<0.0005) Hb levels, and significantly higher (p<0.0005) creatinine levels compared to the control group. The median EPO in group I and II were significantly higher (p=0.002; p=0.018), while median EPO

2017 Journal of medical biochemistry

99. Screening for Chronic Kidney Disease in Adult Males in Vojvodina: A Cross-sectional Study Full Text available with Trip Pro

Screening for Chronic Kidney Disease in Adult Males in Vojvodina: A Cross-sectional Study Chronic kidney disease (CKD) is one of the most significant global health problems accompanied by numerous complicatons, with constant increase in the number of affected people. This number is much higher in early phases of disease and patients are mostly asymptomatic, so early detection of CKD is crucial. The aim was examination of the prevalence of CKD in the general population of males in Vojvodina (...) are the most important CKD risk factors and the level of CKD awareness is extremely low (1.3%) indicating the necessity for introduction of early stage disease recognition measures, including raising CKD awareness.

2017 Journal of medical biochemistry

100. Etelcalcetide (Parsabiv) - To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis

Etelcalcetide (Parsabiv) - To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis Parsabiv (etelcalcetide) Injection U.S. Department of Health and Human Services Search FDA Submit search Parsabiv (etelcalcetide) Injection Parsabiv Company: Amgen, Inc. Application No.: 208325 Approval Date: 02/07/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package